Bicycle Therapeutics, plc

With many big pharmas anxious to fill their portfolios with new commercial sellers and biotechs running low on cash, 2025 is expected to be a big year for deals and M&A across the biopharma sector

Lykos Therapeutics , still reeling from US Food and Drug Administration rejection of the company’s capsule formulation of the psychedelic drug midomafetamine for the treatment of post-traumatic stress

Corbus Pharmaceuticals is continuing a share price growth streak as investors warm to its plans for an antibody drug conjugate (ADC) to compete with Pfizer and an obesity drug to rival Novo Nordis

Cytokinetics, Inc. CEO Robert Blum has maintained since the company reported positive topline Phase III results for the cardiac myosin inhibitor aficamten in obstructive hypertrophic cardiomyopathy (